An FDA spokesperson told CNBC the agency will review the information, as it is set to vote on the vaccine’s emergency use authorization.
Unlike Pfizer and Moderna, Novavax isn’t mRNA-based — a component that was shown to be more effective at protecting against COVID-19. With a 90 percent efficacy rate, the potential fourth option for a vaccine was also clinically tested before the omicron variant swept across the U.S.
Before Novavax is rolled out, the FDA and CDC will have to authorize it.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
